Perimenopause weight gain that resists diet and exercise is most often driven by rising insulin resistance, not a drop in discipline. Declining and fluctuating estrogen directly impairs how your cells respond to insulin, and that shift can happen even when your habits haven't changed at all.
You've cut sugar. You're tracking your steps. You're sleeping when you can and skipping the wine more nights than not.
And the number on the scale hasn't moved in months.
If you've started wondering whether something is wrong with your discipline, I want to stop you there. Nothing is wrong with your discipline. Something is wrong with the math your body is currently running, and that math has a name.
What Estrogen Has to Do With Your Insulin
In perimenopause, estrogen doesn't decline in a straight line. It swings, and one of the things it takes with it is your cells' ability to respond to insulin efficiently. Estrogen receptors are present throughout fat and muscle tissue, where they help regulate how glucose is taken up and used. When estrogen becomes erratic, that regulation becomes inconsistent too.
When insulin resistance increases, your body holds onto blood sugar longer, stores more of it as fat (especially around your midsection), and resists releasing that fat even when you're eating less than you used to.
This is happening at the cellular level. It has nothing to do with how hard you're trying.
The GLP-1 Conversation Getting Louder
You've probably noticed this conversation getting louder lately, mostly around GLP-1 medications like semaglutide and tirzepatide. And the appeal makes sense. If your body has stopped responding to the basics that used to work, a tool that directly addresses insulin and appetite regulation sounds like relief.
Here's what I'd ask before reaching for it, though: has anyone actually looked at why your insulin response changed in the first place?
"The first question isn't whether a GLP-1 will work. It's what's actually driving the resistance it's being asked to override."
For most of my patients, the answer to that first question is no. They were offered a prescription before anyone ran a fasting insulin, checked their thyroid beyond TSH, or looked at how their cortisol pattern is interacting with their blood sugar throughout the day. They were treated for a symptom that has multiple possible drivers, and none of those drivers were ever identified.
The Tradeoffs Nobody Mentions
That matters, because GLP-1s come with real tradeoffs in this population, and they're rarely part of the initial conversation.
In the SURMOUNT-1 trial's DXA substudy, women on tirzepatide lost 10.9 percent of their lean body mass over 72 weeks, compared to 2.6 percent on placebo (source: Jeremy Burnham, MD). Roughly a quarter of the total weight lost on tirzepatide was lean mass rather than fat. In semaglutide's STEP 1 DXA subset, that proportion has approached 40 percent.
Lean mass loss matters more than it sounds like it should, because muscle is what helps stimulate and maintain bone density. Women in menopause are already losing bone at an accelerated rate as estrogen declines. Layering rapid weight loss, and the muscle loss that comes with it, on top of that decline is what bone health researcher Dr. Wendy Kohrt has called a "perfect storm" (source: UC Health).
None of that means the medication is wrong for everyone. It means it shouldn't be the first question, and it shouldn't be started without a baseline understanding of what you're working with.
What Actually Drives the Resistance
The first question is what's actually driving the resistance. In my practice, it's usually one or more of these:
- Cortisol dysregulation: chronically elevated cortisol raises blood sugar directly and worsens insulin sensitivity over time
- Thyroid function that's technically "normal" but underperforming: a TSH within range doesn't confirm your cells are getting adequate thyroid hormone, and thyroid status affects metabolic rate and glucose handling
- Nutrient depletion: magnesium, chromium, and B vitamins are all involved in insulin signaling, and depletion is common and rarely tested
- The estrogen swings themselves: addressed directly through cycle support rather than worked around indefinitely
Each of those has a different fix, and most of them are findable with the right labs.
What to Ask Before Starting Anything
If stubborn weight is part of your picture, a few questions are worth bringing to your next appointment, whether or not a GLP-1 is on the table:
- Has my fasting insulin been tested, not just fasting glucose?
- Was my thyroid panel limited to TSH, or did it include free T3?
- Has anyone looked at my cortisol pattern across the day?
- If a GLP-1 is being discussed, has a baseline DXA scan been recommended?
You are not looking for permission to try something. You are looking for a complete picture before you do.
Take a Closer Look at What's Behind the Resistance
The Why Am I So Tired Assessment is a short, targeted assessment designed to connect your symptoms, including stubborn weight, to the hormone and metabolic patterns most likely driving them. It won't replace a full clinical workup, but it will give you a clearer picture of what to look at next.
FAQ Section
Why can't I lose weight in perimenopause even with diet and exercise?
The most common driver is rising insulin resistance caused by fluctuating estrogen, which changes how your cells respond to insulin and where your body stores fat. This shift can happen even when your diet and activity level haven't changed, which is why the usual strategies stop working as well as they used to.
Is it safe to take a GLP-1 medication during perimenopause?
GLP-1s can be appropriate for some women, but they come with tradeoffs that are specific to this life stage, including lean mass loss and accelerated bone density decline on top of menopause-related bone loss. A baseline DXA scan and a workup into what's driving insulin resistance are reasonable steps before starting.
How much muscle do you lose on GLP-1 medications?
In the SURMOUNT-1 DXA substudy, tirzepatide use was associated with a 10.9 percent reduction in lean body mass over 72 weeks, compared to 2.6 percent with placebo. Roughly a quarter to as much as 40 percent of total weight lost on GLP-1s can be lean mass rather than fat, depending on the medication and study.
What labs should I ask for if my weight won't move in perimenopause?
A useful starting point includes fasting insulin alongside fasting glucose, a full thyroid panel including free T3 (not just TSH), and a look at your cortisol pattern across the day. These go beyond a standard panel and each one has a direct connection to insulin resistance.
Can thyroid problems cause weight gain even with normal TSH?
Yes. A TSH within conventional range does not confirm that your cells are receiving adequate thyroid hormone. Subtle thyroid underperformance can affect metabolic rate and glucose handling well before TSH moves outside of standard reference ranges.
Why does fat distribution change in perimenopause specifically?
Estrogen receptors are present throughout fat tissue and influence where fat is stored. As estrogen becomes erratic in perimenopause, fat distribution tends to shift toward the midsection, independent of total weight change, which is why waist circumference often increases even without significant weight gain.